In vivo visualization of synuclein deposits in Parkinson's disease and its clinical applicability

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461303
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurology
• Research Institution: Tohoku University
• Principal Investigator: Kikuchi Akio 東北大学, 医学系研究科, 助教 (80463785)
• Research Collaborator: TAKEDA Atsushi 独立行政法人国立病院機構, 仙台西多賀病院, 院長 (70261534) ; OKAMURA Nobuyuki 東北医科薬科大学, 医学部, 教授 (40361076) ; FURUMOTO Shozo 東北大学, サイクロトロン・ラジオアイソトープセンター, 教授 (00375198) ; TASHIRO Manabu 東北大学, サイクロトロン・ラジオアイソトープセンター, 教授 (00333477) ; FUNAKI Yoshihito 東北大学, サイクロトロン・ラジオアイソトープセンター, 講師 (50261491)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: パーキンソン病 / PET / [11C] BF-227 / α-シヌクレイン

Outline of Final Research Achievements

The histopathological hallmark of Parkinson's disease (PD) is the appearance of Lewy bodies, which are mainly composed of α-synuclein fibrils. In vivo visualization of α-synuclein depositis should be for the assessment of therapy and severity of pathological progression in PD. We aimed to evaluate whether carbon-11-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy) benzoxazole ([11C] BF-227) positron emission tomography (PET) can detect α-synuclein deposits in patients with PD. PD patients showed high uptake in precentral and postcentral cortices compared to normal controls. [11C] BF-227 showed time-dependent increases of tracer uptake in amygdala, anterior cingulate cortex, insula and globus pallidus, etc., in PD patients. Our data suggest that [11C] BF-227 PET can detect α-synuclein deposits and be used as a surrogate marker in PD patients.

Free Research Field

神経内科